secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001714899-24-000233
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics amends bylaws for universal proxy and Delaware law updates
------------------------------------------------------------------------------

- Board approved amended restated bylaws effective November 12, 2024.
- Updates advance notice procedures for director nominations and stockholder proposals.
- Requires stockholder to show Rule 14a-19 compliance 5 business days before meeting.
- Conforms provisions to current Delaware General Corporation Law.
- Updates provisions on directors, board committees, officers, and ministerial changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000233/0001714899-24-000233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000233/dnli-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer